The Knight ADRC has supported many investigators at Washington University and at other institutions over the years. We wish to avoid the situation where two investigators study the same research question to avoid duplication of effort and potential conflict. To determine if your topic has already been studied with our resources, please search our database. If you find that your topic or a related topic has been submitted, you may wish to contact the investigator to inquire about their findings to determine how you might proceed. You may wish to collaborate or modify your request to avoid overlap. The results below reflect requests made since online requests have been accepted. As such, not all fields will have data as certain information, such as aims, were not collected until recently. If an entry has been assigned an ID number (e.g. T1004), the full request has been submitted and is either approved, disapproved or in process. If an entry has no ID number, then it represents a submission that has not yet been reviewed. Search terms are applied across an entire requests application including variables not displayed below. A more specific, detailed search may yield better results depending upon your needs.
Search Terms:
Investigator: Michael Cole
Project Title: Examining changes in functional network structure
Date: December 21, 2021 at 5:18 pm
Request ID: D1619
Aim 1: Examine changes in functional fMRI networks during task and resting state
Aim 2: Relate differences in network structure to Alzheimer biomarkers
Aim 3: Calculate changes in network structure in two different resting state scans
Aim 4: Use differences in longitudinal resting state structure to predict longitudinal cognition
Investigator: Anne Fagan Niven
Project Title: Lumipusle exploratory inquiry for autopsy/ CSF data
Date: December 21, 2021 at 5:18 pm
Request ID: D1620
Aim 1: To determine the feasibility (as measured by cohort size and potential for statistical significance) of a collaboration with Fujirebio that would explore correspondence of positive AD autopsy and previously collected CSF analytes (Abeta, tau and ptau181).
Aim 2:
Aim 3:
Aim 4:
Investigator: Anne Fagan
Project Title: Roche Elecsys automated CSF assay for Ab42, tau and ptau181
Date: December 21, 2021 at 5:18 pm
Request ID: D1706
Aim 1: Evaluate the correspondence between CSF Elecsys data and amyloid PET
Aim 2: Evaluate the ability of CSF Elecsys data to predict cognitive decline
Aim 3: Evaluate the ability of CSF Elecsys data to discriminate clinical groups
Aim 4: Evaluate the analytical performance between Elecsys and INNOTEST CSF data
Investigator: Catherine roe
Project Title: Preliminary data for Mike Wiener project on behalf of JCM
Date: December 21, 2021 at 5:18 pm
Request ID: D1705
Aim 1: To compare ability of AD8 and CDR to predict AD dementia
Aim 2:
Aim 3:
Aim 4:
Investigator: Jee-young Han
Project Title: Clinical outcomes and its predictors in CDR 0.5, uncertain dementia
Date: December 21, 2021 at 5:18 pm
Request ID: D1704
Aim 1: To define and differentiate clinical characteristics of CDR 0.5, uncertain dementia
Aim 2: To demonstrate the clinical outcomes of CDR 0.5, uncertain dementia
Aim 3: To determine predictors of progression of CDR 0.5, uncertain dementia to AD
Aim 4:
Investigator: Arnaud Charil
Project Title: Potential usage of diffusion basis spectrum imaging (DBSI) to assess white matter inflammation in Alzheimer�s disease
Date: December 21, 2021 at 5:18 pm
Request ID: D1703
Aim 1: Generate a normative profile (across brain regions/tracts and subjects) of DBSI parameters, suitable for expressing (defining) �abnormal� levels of these parameters
Aim 2: Explore the profile of abnormalities in the different DBSI parameters in more advanced NIA-AA stage individuals
Aim 3: Refine potential analysis strategies for application to clinical trials
Aim 4:
Investigator: Sergey Shcherbinin
Project Title: Potential usage of PET-based perfusion measurements as candidates neurodegeneration biomarkers
Date: December 21, 2021 at 5:18 pm
Request ID: D1702
Aim 1: Analyze dynamic PET images obtained using different radiotracers
Aim 2: Optimize time window to measure perfusion using PET tracers
Aim 3: Perform cross-sectional and longitudinal comparison between perfusion measures and other biomarkers/scores
Aim 4:
Investigator: Samantha Allison
Project Title: Relationship between proton pump inhibitors and risk of dementia, cognition, brain structure, and Alzheimer disease biomarkers
Date: December 21, 2021 at 5:18 pm
Request ID: D1701
Aim 1: Examine the relationship between proton pump inhibitors and both risk of dementia and longitudinal change in cognition.
Aim 2: Examine the relationship between proton pump inhibitors and biological markers of Alzheimer disease (e.g., regional based brain volumes obtained via structural MRI, amyloid PET, and CSF biomarkers).
Aim 3:
Aim 4:
Investigator: Jee-young Han
Project Title: 2. Characteristics of atypical AD and use of amyloid markers
Date: December 21, 2021 at 5:18 pm
Request ID: D1622
Aim 1: To demonstrate prevalence of amyloid biomarkers in atypical dementia (non-AD dementia(uncertain or mixed) and AD with unusual features)
Aim 2: To determine the utility of amyloid biomarkers in diagnosing atypical AD in atypical dementia
Aim 3: To characterize atypical dementia in MAP cohort
Aim 4: To determine rate of cognitive decline in atypical AD dementia and non-AD dementia
Investigator: Dmitriy A. Yablonskiy
Project Title: Quantitative Evaluation of Changes in the AD brain Using Advanced MRI
Date: December 21, 2021 at 5:18 pm
Request ID: D1621
Aim 1: To develop a readily available, non-invasive quantitative in vivo MRI-based biomarker that can serve as a surrogate for amyloid-β accumulation in the brain
Aim 2: To establish specific quantitative and spatial patterns of GEPCI metrics abnormalities that would distinguish between normal brain, preclinical AD, and very mild AD
Aim 3: To establish the effect of early AD-related brain tissue damage (defined by GEPCI surrogate biomarkers) on cognitive performance and to test the hypothesis that the GEPCI metrics and/or changes in GEPCI metrics can be predictors of the disease progression
Aim 4: To validate GEPCI measurements against direct neuropathology